Form 8-K - Current report:
SEC Accession No. 0001558370-24-015525
Filing Date
2024-11-13
Accepted
2024-11-13 16:10:47
Documents
16
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adap-20241113x8k.htm   iXBRL 8-K 39677
2 EX-99.1 adap-20241113xex99d1.htm EX-99.1 339196
3 GRAPHIC adap-20241113xex99d1001.jpg GRAPHIC 10901
4 GRAPHIC adap-20241113xex99d1002.jpg GRAPHIC 4097
  Complete submission text file 0001558370-24-015525.txt   545254

Data Files

Seq Description Document Type Size
5 EX-101.SCH adap-20241113.xsd EX-101.SCH 3507
6 EX-101.LAB adap-20241113_lab.xml EX-101.LAB 15975
7 EX-101.PRE adap-20241113_pre.xml EX-101.PRE 10794
18 EXTRACTED XBRL INSTANCE DOCUMENT adap-20241113x8k_htm.xml XML 4964
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 241454281
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)